Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials

References

• U.S. Department of Health & Human Services. Office of Minority Health . Diabetes and African Americans. Available from http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlid=18. Accessed May 14, 2014.
   Google Scholar
• International Diabetes Federation 2012. Clinical Guidelines Taskforce. Global Guideline for Type 2 Diabetes 2012. Available from http://www.idf.org/publications/global-guideline-type-2-diabetes. Accessed February 3, 2014.
   Google Scholar
• Lopes AA . End-stage renal disease due to diabetes in racial/ethnic minorities and disadvantaged populations. Ethn Dis 2009;19:S1-47-51.
   PubMed Web of Science ®Google Scholar
• Campbell JA , Walker RJ , Smalls BL , Egede LE . Glucose control in diabetes: the impact of racial differences on monitoring and outcomes. Endocrine 2012;42:471–82.
   PubMed Web of Science ®Google Scholar
• Goldberg JB , Goodney PP , Cronenwett JL , Baker F . The effect of risk and race on lower extremity amputations among Medicare diabetic patients. J Vasc Surg 2012;56:1663–8.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health & Human Services. Office of Minority Health . Obesity and African Americans. Available from http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=4&lvlID=25. Accessed October 15, 2014.
   Google Scholar
• Warren TY , Wilcox S , Dowda M , Baruth M . Independent association of waist circumference with hypertension and diabetes in African American women, South Carolina, 2007-2009. Prev Chronic Dis 2012;9:E105.
   PubMed Web of Science ®Google Scholar
• Palmer ND , McDonough CW , Hicks PJ , Roh BH , Wing MR , An SS , et al. A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One 2012;7:e29202.
   PubMed Web of Science ®Google Scholar
• Cheng CY , Reich D , Haiman CA , Tandon A , Patterson N , Selvin E , et al. African ancestry and its correlation to type 2 diabetes in African Americans: a genetic admixture analysis in three U.S. population cohorts. PLoS One 2012;7:e32840.
   PubMed Web of Science ®Google Scholar
• Maty SC , James SA , Kaplan GA . Life-course socioeconomic position and incidence of diabetes mellitus among blacks and whites: the Alameda County Study, 1965-1999. Am J Public Health 2010;100:137–45.
   PubMed Web of Science ®Google Scholar
• Signorello LB , Schlundt DG , Cohen SS , Steinwandel MD , Buchowski MS , McLaughlin JK , et al. Comparing diabetes prevalence between African Americans and Whites of similar socioeconomic status. Am J Public Health 2007;97:2260–7.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE , Bergenstal RM , Buse JB , Diamant M , Ferrannini E , Nauck M , et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–79.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE , Bergenstal RM , Buse JB , Diamant M , Ferrannini E , Nauck M , et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–9.
   PubMed Web of Science ®Google Scholar
• Mount DL , Davis C , Kennedy B , Raatz S , Dotson K , Gary-Webb TL , et al. Factors influencing enrollment of African Americans in the Look AHEAD trial. Clin Trials 2012;9:80–9.
   PubMed Web of Science ®Google Scholar
• Corbie-Smith G , St George DM , Moody-Ayers S , Ransohoff DF . Adequacy of reporting race/ethnicity in clinical trials in areas of health disparities. J Clin Epidemiol 2003;56:416–20.
   PubMed Web of Science ®Google Scholar
• Ard JD , Durant RW , Edwards LC , Svetkey LP . Perceptions of African-American culture and implications for clinical trial design. Ethn Dis 2005;15:292–9.
   PubMed Web of Science ®Google Scholar
• Gallwitz B , Rosenstock J , Rauch T , Bhattacharya S , Patel S , von Eynatten M , et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012;380:475–83.
   PubMed Web of Science ®Google Scholar
• Haak T , Meinicke T , Jones R , Weber S , von Eynatten M , Woerle HJ . Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012;14:565–74.
   PubMed Web of Science ®Google Scholar
• Owens DR , Swallow R , Dugi KA , Woerle HJ . Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011;28:1352–61.
   PubMed Web of Science ®Google Scholar
• Gomis R , Espadero RM , Jones R , Woerle HJ , Dugi KA . Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:653–61.
   PubMed Web of Science ®Google Scholar
• Del Prato S , Barnett AH , Huisman H , Neubacher D , Woerle HJ , Dugi KA . Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13:258–67.
   PubMed Web of Science ®Google Scholar
• Taskinen MR , Rosenstock J , Tamminen I , Kubiak R , Patel S , Dugi KA , Woerle HJ . Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65–74.
   PubMed Web of Science ®Google Scholar
• Barnett AH , Huisman H , Jones R , von Eynatten M , Patel S , Woerle HJ . Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382:1413–23.
   PubMed Web of Science ®Google Scholar
• Yki-Järvinen H , Rosenstock J , Durán-Garcia S , Pinnetti S , Bhattacharya S , Thiemann S , et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Diabetes Care 2013;36:3875–81.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . EMEA/H/C/002110-IG/0350/G-Trajenta: EPAR-product information. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002110/WC500115745.pdf. Accessed July 13, 2014.
   Google Scholar
• U.S. Food and Drug Administration . TRADJENTA (linagliptin). product information. Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/201280s009lbl.pdf. Accessed July 17, 2014.
   Google Scholar
• Thrasher J , Daniels K , Patel S , Whetteckey J , Woerle HJ . Efficacy and safety of linagliptin in Black/African American patients with type 2 diabetes: a 6-month, randomized, double-blind, placebo-controlled study. Endocr Pract 2014;20:412–20.
   PubMed Web of Science ®Google Scholar
• Friedrich C , Emser A , Woerle HJ , Graefe-Mody U . Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes. Am J Ther 2013;20:618–21.
   PubMed Web of Science ®Google Scholar
• Graefe-Mody U , Friedrich C , Port A , Ring A , Retlich S , Heise T , et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011;13:939–46.
   PubMed Web of Science ®Google Scholar
• Friedrich C , Glund S , Lionetti D , Kissling CJ , Righetti J , Patel S , et al. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2013;76:445–54.
   PubMed Web of Science ®Google Scholar
• Barnett AH , Patel S , Harper R , Toorawa R , Thiemann S , von Eynatten M , Woerle HJ . Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension. Diabetes Obes Metab 2012;14:1145–54.
   PubMed Web of Science ®Google Scholar
• Lewin AJ , Arvay L , Liu D , Patel S , von Eynatten M , Woerle HJ . Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2012;34:1909–19; e15.
   PubMed Web of Science ®Google Scholar
• Bajaj M , Gilman R , Patel S , Kempthorne-Rawson J , Woerle H-J . Linagliptin improved glycemic control without weight gain or hypoglycemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone. Poster 1093-P Paper presented at: 73rd Scientific Sessions, American Diabetes Association; 2013 June 21–25; Chicago, IL, USA.
   Google Scholar
• Garber AJ , Abrahamson MJ , Barzilay JI , Blonde L , Bloomgarden ZT , Bush MA , et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327–36.
   PubMed Web of Science ®Google Scholar
• Davidson JA , Lajara R , Aguilar RB , Mattheus M , Woerle H-J , von Eynatten M . Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials. BMJ Open Diabetes Res Care 2014;2:e000020.
   PubMedGoogle Scholar
• Kawamori R , Inagaki N , Araki E , Watada H , Hayashi N , Horie Y , et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012;14:348–57.
   PubMed Web of Science ®Google Scholar
• Zeng Z , Yang JK , Tong N , Yan S , Zhang X , Gong Y , Woerle HJ . Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial. Curr Med Res Opin 2013;29:921–9.
   PubMed Web of Science ®Google Scholar
• American College of Physicians . Racial and ethnic disparities in health care, updated 2010. A position paper of the American College of Physicians. May 13, 2010. Philadelphia: American College of Physicians; 2010: Policy Paper. Available from American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106, USA. Available from http://www.acponline.org/advocacy/current_policy_papers/assets/racial_disparities.pdf. Accessed August 06, 2014.
   Google Scholar
• Powell JH , Fleming Y , Walker-McGill CL , Lenoir M . The project IMPACT experience to date: increasing minority participation and awareness of clinical trials. J Natl Med Assoc 2008;100:178–87.
   PubMed Web of Science ®Google Scholar
• McGill JB . Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. Ther Adv Endocrinol Metab 2012;3:113–24.
   PubMedGoogle Scholar
• Velásquez-Mieyer P , Cowan PA , Pérez-Faustinelli S , Nieto-Martínez R , Villegas-Barreto C , Tolley EA , et al. Racial disparity in glucagon-like peptide 1 and inflammation markers among severely obese adolescents. Diabetes Care 2008;31:770–5.
   PubMed Web of Science ®Google Scholar
• Higgins PB , Férnández JR , Garvey WT , Granger WM , Gower BA . Entero-insular axis and postprandial insulin differences in African American and European American children. Am J Clin Nutr 2008;88:1277–83.
   PubMed Web of Science ®Google Scholar
• Velásquez-Mieyer PA , Cowan PA , Umpierrez GE , Lustig RH , Cashion AK , Burghen GA . Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects. Int J Obes Relat Metab Disord 2003;27:1359–64.
   PubMed Web of Science ®Google Scholar
• Williams LK , Padhukasahasram B , Ahmedani BK , Peterson EL , Wells KE , González Burchard E , Lanfear DE . Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 2014;99:3160–8.
   PubMed Web of Science ®Google Scholar
• White WB , Cannon CP , Heller SR , Nissen SE , Bergenstal RM , Bakris GL , et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327–35.
   PubMed Web of Science ®Google Scholar
• Mosenzon O , Raz I , Scirica BM , Hirshberg B , Stahre CI , Steg PG , et al. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 2013;29:417–26.
   PubMed Web of Science ®Google Scholar
• Marshall MC Jr . Diabetes in African Americans. Postgrad Med J 2005;81:734–40.
   PubMed Web of Science ®Google Scholar
• Shenolikar RA , Balkrishnan R , Camacho FT , Whitmire JT , Anderson RT . Race and medication adherence in Medicaid enrollees with type-2 diabetes. J Natl Med Assoc 2006;98:1071–7.
   PubMed Web of Science ®Google Scholar
• Hauber AB , Mohamed AF , Johnson FR , Falvey H . Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med 2009;26:416–24.
   PubMed Web of Science ®Google Scholar
• Nwabuo CC , Dy SM , Weeks K , Young JH . Factors associated with appointment non-adherence among African-Americans with severe, poorly controlled hypertension. PLoS One 2014;9:e103090.
   PubMed Web of Science ®Google Scholar
• Johansen OE , Neubacher D , von Eynatten M , Patel S , Woerle HJ . Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3.
   PubMed Web of Science ®Google Scholar
• von Eynatten M , Gong Y , Emser A , Woerle HJ . Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol 2013;12:60.
   PubMed Web of Science ®Google Scholar
• Lehrke M , Marx N , Patel S , Seck T , Crowe S , Cheng K , et al. Safety and tolerability of linagliptin in patients with type 2 diabetes: A comprehensive pooled analysis of 22 placebo-controlled studies. Clin Ther 2014;36:1130–46.
   PubMed Web of Science ®Google Scholar
• Lajara R , Aguilar R , Hehnke U , Woerle HJ , von Eynatten M . Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, Phase III trials. Clin Ther 2014;36:1595–605.
   PubMed Web of Science ®Google Scholar
• Schernthaner G , Barnett AH , Emser A , Patel S , Troost J , Woerle HJ , von Eynatten M . Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:470–8.
   PubMed Web of Science ®Google Scholar
• Marx N , Rosenstock J , Kahn SE , Zinman B , Kastelein JJ , Lachin JM , et al. Baseline characteristics of participants enrolled in the CARdiovascular Outcome study of LINAgliptin versus glimepiride in early type 2 diabetes (CAROLINA). Abstract 2358-PO. Paper presented at: 73rd Scientific Sessions, American Diabetes Association; 2013 June 21–25; Chicago, IL, USA.
   Google Scholar
• Groop PH , Cooper ME , Perkovic V , Emser A , Woerle HJ , von Eynatten M . Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013;36:3460–8.
   PubMed Web of Science ®Google Scholar